HEPHAISTOS-Pharma
biotechnology company developing next-generation immunotherapies against cancer that target innate immunity to increase patient cure rates
HEPHAISTOS-Pharma has raised €4.3M across 1 funding round from 4 investors, most recently a Seed round in May 2024. Based in Orsay, France; active in Healthtech. Data as of 28 Oct 2026.
Orsay, Francehephaistos-pharma.fr ↗
Total raised
€4.3M
€4,300,000
Funding rounds
1
Investors
4
distinct backers
Active since
2024-05
latest 2024-05
Funding by year
EUR raised per yearHEPHAISTOS-Pharma — funding by year — interactive chart.
Data table
| HEPHAISTOS-Pharma — funding by year | |
|---|---|
| 2024 | €4.3M |
Signals
High confidenceRaise-next likelihood9
base rate 44% for Seed
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-05-16 | Seed | €4.3M | Elaia Partners,Fondation Fournier-Majoie,Noshaq,xista science ventures | View deal → |
Related news
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData